Claims
- 1. An isolated nucleic acid molecule, comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
(a) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 169 in SEQ ID NO:2; (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about 2 to about 169 in SEQ ID NO:2; (c) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97640; and (d) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), or (c).
- 2. An isolated nucleic acid molecule, comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a), (b), (c), or (d) of claim 1 wherein said polynucleotide which does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A residues or of only T residues.
- 3. An isolated nucleic acid molecule, comprising a polynucleotide which encodes the amino acid sequence of an epitope-bearing portion of an endokine alpha polypeptide having an amino acid sequence in (a), (b), (c), or (d) of claim 1.
- 4. An isolated nucleic acid molecule of claim 3, which encodes an epitope-bearing portion of an endokine alpha polypeptide selected from the group consisting of: a polypeptide comprising amino acid residues from about 44 to about 158 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 44 to about 54 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 57 to about 68 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 69 to about 78 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 94 to about 105 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 108 to about 132 in SEQ ID NO:2; and a polypeptide comprising amino acid residues from about 148 to about 158 in SEQ ID NO:2.
- 5. An isolated nucleic acid molecule, comprising a polynucleotide having a sequence selected from the group consisting of:
(a) a nucleotide sequence ofa fragment of the sequence shown in SEQ ID NO:1 wherein said fragment comprises at least 50 contiguous nucleotides from SEQ ID NO: 1, provided that said isolated nucleic acid molecule is not a fragment starting at nucleotide 26 and ending at nucleotide 476 of SEQ ID NO: 1, or a subfragment thereof; and (b) a nucleotide sequence complementary to a nucleotide sequence in (a).
- 6. A method for making a recombinant vector, comprising inserting an isolated nucleic acid molecule of claim 1 into a vector.
- 7. A recombinant vector produced by the method of claim 6.
- 8. A method of making a recombinant host cell, comprising introducing the recombinant vector of claim 7 into a host cell.
- 9. A recombinant host cell produced by the method of claim 8.
- 10. A recombinant method for producing an endokine alpha polypeptide, comprising culturing the recombinant host cell of claim 9 under conditions such that said polypeptide is expressed and recovering said polypeptide.
- 11. An isolated endokine alpha polypeptide having an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
(a) amino acids from about 1 to about 169 in SEQ ID NO:2; (b) amino acids from about 2 to about 169 in SEQ ID NO:2; (c) the amino acid sequence of the endokine alpha polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97640; and (d) the amino acid sequence of an epitope-bearing portion of any one of the polypeptides of (a), (b), or (c).
- 12. An isolated polypeptide of claim 11, comprising an epitope-bearing portion of endokine alpha, wherein said portion is selected from the group consisting of: a polypeptide comprising amino acid residues from about 44 to about 158 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 44 to about 54 in SEQ ID NO:2; apolypeptide comprising amino acid residues from about 57 to about 68 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 69 to about 78 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 94 to about 105 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 108 to about 132 in SEQ ID NO:2; and a polypeptide comprising amino acid residues from about 148 to about 158 in SEQ ID NO:2.
- 13. An isolated polypeptide of claim 11, which is produced or contained in a recombinant host cell.
- 14. An isolated polypeptide of claim 13, wherein said recombinant host cell is mammalian.
- 15. An isolated nucleic acid molecule, comprising a polynucleotide encoding an endokine alpha polypeptide wherein, except for one to fifty conservative amino acid substitutions, said polypeptide has a sequence selected from the group consisting of:
(a) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 169 in SEQ ID NO:2; (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about 2 to about 169 in SEQ ID NO:2; (c) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No.97640; and (d) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), or (c).
- 16. An isolated endokine alpha polypeptide wherein, except for one to fifty conservative amino acid substitutions, said polypeptide has a sequence selected from the group consisting of:
(a) amino acids from about 1 to about 169 in SEQ ID NO:2; (b) amino acids from about 2 to about 169 in SEQ ID NO:2; (c) the amino acid sequence of the endokine alpha polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97640; and (d) the amino acid sequence of an epitope-bearing portion of any one of the polypeptides of (a), (b), or (c).
- 17. An isolated antibody or antibody fragment that binds specifically to an endokine alpha polypeptide of claim 11.
- 18. A method for treating an individual in need of a decreased level of endokine alpha activity, comprising
administering to said individual a composition comprising the isolated antibody or antibody fragment of claim 17.
- 19. A method of treating an individual having a disorder selected from the group consisting of: AIDS, chronic lymphocyte disorder, common variable immunodeficiency, a tumor, parasitic disease, autoimmune diseases, lupus, arthritis, idiopathic thrombocytopenic purpura, multiple sclerosis, chronic inflammation, acute inflammation, acute allograft rejection, graft versus host disease, transplant rejection, fetal resorption, fecal peritonitis, skin allergies, bowel disease, a wound, sepsis, ALL, Hodgkins disease, non-Hodgkins lymphoma, chronic lymphocyte leukemia, plasmacytomas, multiple myeloma, Burkitt's lymphoma, EBV-transformed diseases, chronic myelogenous leukemia, chronic hypergammaglobulinemeia, autoimmune hematological disorders, polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune thyroiditis, idiopathic Addison's disease, vitilogo, gluten-sensitive enteropathy, autoimmune neutropenias, pemphigus vulgaris, Goodpasture's disease, bullous pemphigoid, discoid lupus, dense deposit disease, endocrine ophthalmopathy, IBD, asthma, Graves disease, sarcoidosis, cirrhosis, juvenile diabetes, insulin dependent diabetes mellitus, uveitis, autoimmune gastritis, lymphopenias, polyarteritis nodosa, Sjogren's syndrome, Bechet's disease, Hashimoto's disease, primary myxedema, polymyositis, mixed connective tissue disease, keratoconjunctivitis sicca, vernal keratoconjunctivitis, interstitial lung fibrosis, glomerulonephritis, hepatitis, autoimmune hemolytic anemia, contact sensitivity disease, monophasic EAE, SCIDS, Alzheimer's disease, Parkinson's disease and primary lateral sclerosis;
wherein said method comprises administering to the individual a therapeutically effective amount of an endokine-α polypeptide selected from the group consisting of: (a) the polypeptide of claim 11; and (b) the polypeptide of claim 16.
- 20. A method oftreating an individual having a disorder selected from the group consisting of: autoimmune diseases, silicosis, sarcoidosis, idiopathic pulmonary fibrosis, idiopathic hyper-eosinophilic syndrome, endotoxic shock, atherosclerosis, histamine-mediated allergic reactions, IgE-mediated allergic reactions, chronic inflammation, acute inflammation, rheumatoid arthritis, aplastic anemia, myelodysplastic syndrome, and a wound;
wherein said method comprises administering to the individual a therapeutically effective amount of an endokine-a antagonist.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 60/136,788, filed May 28, 1999, which disclosure is herein incorporated by reference, and No. 60/122,099, filed Feb. 26, 1999, which disclosure is herein incorporated by reference; this application is also a continuation-in-part of Appl. No. 09/345,790, filed Jul. 1, 1999, which disclosure is herein incorporated by reference; said Ser. No. 09/345,790 is a division of U.S. Appl. No. 08/912,227, filed Aug. 15, 1997, U.S. Pat. No. 5,998,171, which disclosure is herein incorporated by reference; said 08/912,227 claims the benefit of U.S. Appl. No. 60/024,058, filed Aug. 16, 1996, which disclosure is herein incorporated by reference.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60136788 |
May 1999 |
US |
|
60122099 |
Feb 1999 |
US |
|
60024058 |
Aug 1996 |
US |
Divisions (3)
|
Number |
Date |
Country |
Parent |
09513584 |
Feb 2000 |
US |
Child |
10136511 |
May 2002 |
US |
Parent |
09345790 |
Jul 1999 |
US |
Child |
10136511 |
May 2002 |
US |
Parent |
08912227 |
Aug 1997 |
US |
Child |
09345790 |
Jul 1999 |
US |